Peptide Stack · Research protocol
The Epithalon + MOTS-c + NAD+ longevity stack
Three peptides targeting three independent aging pathways: telomere maintenance, mitochondrial biogenesis, and cellular energy metabolism.
Protocol goal
Support healthy aging by targeting three independent hallmarks of aging: telomere attrition, mitochondrial dysfunction, and NAD+ decline.
Protocol timeline
Adults 40+ interested in preventative anti-aging research protocols. Best paired with resistance training, sleep hygiene, and metabolic health basics.
Active cancer or high cancer risk (telomerase activation is theoretical concern). Pregnancy. Under 30.
Frequently asked questions
What is the Khavinson protocol?
Vladimir Khavinson pioneered short-peptide bioregulator research in Russia. His epithalon protocol is 10 consecutive days of injections, repeated 2× per year, based on 30+ years of clinical data on institutionalized elderly patients showing reduced all-cause mortality.
Why MOTS-c instead of just NAD+?
MOTS-c is encoded in mitochondrial DNA and acts on the AMPK pathway independently of NAD+. It directly improves mitochondrial function and insulin sensitivity. NAD+ supports sirtuin/PARP function. Different levers, both worth pulling.
Are there human longevity trials?
Not yet at scale — this is research-protocol territory. Epithalon has the longest human data (Khavinson cohort). MOTS-c has early Phase 1 trials. NAD+ has extensive human data on metabolism and cognition.